Should I buy or sell Emergent BioSolutions stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" EBS shares. View EBS analyst ratings or view top-rated stocks .

What is Emergent BioSolutions' stock price target for 2024?

2 equities research analysts have issued 12-month price targets for Emergent BioSolutions' stock. Their EBS share price targets range from $9.00 to $22.00. On average, they predict the company's stock price to reach $15.50 in the next year. This suggests a possible upside of 595.1% from the stock's current price. View analysts price targets for EBS or view top-rated stocks among Wall Street analysts .

How have EBS shares performed in 2023?

Emergent BioSolutions' stock was trading at $11.81 at the start of the year. Since then, EBS stock has decreased by 81.1% and is now trading at $2.23. View the best growth stocks for 2023 here .

Are investors shorting Emergent BioSolutions?

Emergent BioSolutions saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 10,930,000 shares, an increase of 21.9% from the October 15th total of 8,970,000 shares. Based on an average daily volume of 2,330,000 shares, the short-interest ratio is currently 4.7 days. Approximately 22.0% of the company's stock are short sold. View Emergent BioSolutions' Short Interest .

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) posted its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($0.98) by $0.08. The biopharmaceutical company had revenue of $337.90 million for the quarter, compared to analysts' expectations of $216.17 million. Emergent BioSolutions had a negative trailing twelve-month return on equity of 41.78% and a negative net margin of 72.29%. The firm's revenue for the quarter was up 39.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.86) EPS.

What ETF holds Emergent BioSolutions' stock ?

ETFMG Treatments Testing and Advancements ETF holds 14,243 shares of EBS stock, representing 0.70% of its portfolio.

What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?

38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com . Bob Kramer has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA) , Salesforce (CRM) , Novavax (NVAX) , Advanced Micro Devices (AMD) , Block (SQ) , Netflix (NFLX) , Gilead Sciences (GILD) , PayPal (PYPL) , Johnson & Johnson (JNJ) and AbbVie (ABBV) .

Who are Emergent BioSolutions' major shareholders?

Emergent BioSolutions' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Charles Schwab Investment Management Inc. (3.01%), Jacobs Levy Equity Management Inc. (2.41%), Northern Trust Corp (0.94%), Allspring Global Investments Holdings LLC (0.88%), Invesco Ltd. (0.58%) and American Century Companies Inc. (0.58%). Insiders that own company stock include Kathryn C Zoon, Richard S Lindahl , Robert Kramer, Ronald Richard and Sue Bailey. View institutional ownership trends .

How do I buy shares of Emergent BioSolutions?

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Emergent BioSolutions (EBS) Stock Price, News & Analysis

$2.12

-0.37 (-14.86%)

(As of 04:23 PM ET)

Compare

Today's Range: $2.11
▼
$2.48
50-Day Range: $1.82
▼
$3.17
52-Week Range: $1.81
▼
$16.66

Volume: 1.60 million shs
Average Volume: 1.72 million shs
Market Capitalization: $109.84 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.50

Emergent BioSolutions MarketRank™ Stock Analysis

Analyst Rating: Reduce
1.50 Rating Score
Upside/Downside: 595.1% Upside
$15.50 Price Target
Short Interest: Bearish
21.70% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.40
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.96) to $2.31 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

486th out of 943 stocks

Pharmaceutical Preparations Industry

208th out of 422 stocks

2.8

Analyst's Opinion

Consensus Rating
Emergent BioSolutions has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $15.50, Emergent BioSolutions has a forecasted upside of 595.1% from its current price of $2.23.
Amount of Analyst Coverage
Emergent BioSolutions has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
21.70% of the float of Emergent BioSolutions has been sold short.
Short Interest Ratio / Days to Cover
Emergent BioSolutions has a short interest ratio ("days to cover") of 5.1.
Change versus previous month
Short interest in Emergent BioSolutions has recently decreased by 1.37%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Emergent BioSolutions does not currently pay a dividend.
Dividend Growth
Emergent BioSolutions does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Emergent BioSolutions has received a 73.60% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Influenza vaccines", "Cholera vaccines", and "Antibiotics" products. See details.
Environmental Sustainability
The Environmental Impact score for Emergent BioSolutions is -1.40.

1.1

News and Social Media Coverage

Search Interest
4 people have searched for EBS on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
MarketBeat Follows
3 people have added Emergent BioSolutions to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Emergent BioSolutions insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.90% of the stock of Emergent BioSolutions is held by insiders.
Percentage Held by Institutions
88.26% of the stock of Emergent BioSolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Emergent BioSolutions are expected to grow in the coming year, from ($3.96) to $2.31 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Emergent BioSolutions is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Emergent BioSolutions is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Emergent BioSolutions has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Emergent BioSolutions Stock (NYSE:EBS)

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; public health crises; and acute, emergency, and community care. The company offers ACAM2000, a smallpox vaccine; Anthrasil to for inhalational anthrax; Botulism Antitoxin Heptavalent to treat botulinum disease; BioThrax, an anthrax vaccine; Ebanga, a monoclonal antibody to treat infection caused by Zaire ebolavirus; raxibacumab injection for the treatment of inhalational anthrax; reactive skin decontamination lotion kits; TEMBEXA for the treatment of human smallpox disease; Trobigard, an auto-injector atropine sulfate and obidoxime chloride auto-injector for the emergency treatment of known or suspected exposure to nerve agents; and vaccinia immune globulin intravenous that addresses complications from smallpox vaccine. It also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, the company is developing AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; EBS-LASV; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

EBS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EBS Stock News Headlines

December 11, 2023 | finance.yahoo.com

Emergent Biosolutions (EBS) Reports Q3 Loss, Tops Revenue Estimates

December 3, 2023 | benzinga.com

Emergent BioSolutions Stock (NYSE:EBS) Dividends: History, Yield and Dates

December 11, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 29, 2023 | finance.yahoo.com

Emergent (EBS) Gets $75M BARDA Contract for Anthrax Vaccine

November 28, 2023 | finance.yahoo.com

Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)

November 24, 2023 | finance.yahoo.com

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

November 23, 2023 | seekingalpha.com

Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow

November 14, 2023 | morningstar.com

Emergent BioSolutions Inc EBS

December 11, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 10, 2023 | markets.businessinsider.com

Mixed Financial Outlook for Emergent Biosolutions: Strong Narcan Sales Offset by Lowered Guidance and Increased Cash Usage

November 9, 2023 | finance.yahoo.com

Emergent BioSolutions Inc. (NYSE:EBS) Q3 2023 Earnings Call Transcript

November 9, 2023 | finance.yahoo.com

Emergent BioSolutions Inc. (NYSE:EBS) institutional owners may be pleased with recent gains after 83% loss over the past year

November 9, 2023 | finance.yahoo.com

Emergent BioSolutions (EBS) Q3 2023 Earnings Call Transcript

November 8, 2023 | bizjournals.com

Gaithersburg’s Emergent BioSolutions still betting on Narcan nasal spray, becoming ‘more agile’ following cuts

November 8, 2023 | finance.yahoo.com

Emergent BioSolutions Reports Third Quarter 2023 Financial Results

November 7, 2023 | benzinga.com

Earnings Preview For Emergent BioSolutions

October 30, 2023 | finance.yahoo.com

UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023

October 28, 2023 | thestreet.com

Emergent BioSolutions Rises On Unusually High Volume (EBS)

October 19, 2023 | finance.yahoo.com

Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023

October 16, 2023 | finance.yahoo.com

Emergent BioSolutions Partners with Emmitt Smith to Launch Ready to Rescue Campaign to Help Save Lives Amidst Rising Opioid Epidemic

September 7, 2023 | finance.yahoo.com

Why Is Emergent Biosolutions (EBS) Down 22.6% Since Last Earnings Report?

August 30, 2023 | finance.yahoo.com

Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency

August 29, 2023 | msn.com

Benchmark cuts Emergent BioSolutions to hold as company restructures

August 29, 2023 | msn.com

Benchmark Downgrades Emergent Biosolutions (EBS)

August 23, 2023 | finance.yahoo.com

Moody's downgrades Emergent BioSolutions' credit rating, citing unpredictable revenue outlook

August 23, 2023 | msn.com

Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial

August 17, 2023 | finance.yahoo.com

Down -28.45% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS)

See More Headlines

Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/08/2023
Today: 12/11/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NYSE:EBS
CUSIP: 29089Q10
CIK: 1367644
Web: www.emergentbiosolutions.com
Phone: (240) 631-3200
Fax: 301-795-1899
Employees: 2,500
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.50
High Stock Price Target: $22.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +598.2%
Consensus Rating: Reduce
Rating Score (0-4): 1.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($12.08)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-223,800,000.00
Net Margins: -72.29%
Pretax Margin: -67.78%
Return on Equity: -41.78%
Return on Assets: -17.84%

Debt

Debt-to-Equity Ratio: 0.47
Current Ratio: 1.12
Quick Ratio: 0.61

Sales & Book Value

Annual Sales: $1.10 billion
Price / Sales: 0.10
Cash Flow: $0.65 per share
Price / Cash Flow: 3.40
Book Value: $27.72 per share
Price / Book: 0.08

Miscellaneous

Outstanding Shares: 51,807,000
Free Float: 50,823,000
Market Cap: $115.01 million
Optionable: Optionable
Beta: 1.00

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Richard S. Lindahl M.B.A. (Age 59)
Executive VP, CFO & Treasurer
Comp: $799.38k
Ms. Jennifer L. Fox
Executive VP of External Affairs, General Counsel & Corporate Secretary
Mr. Haywood Miller
Interim Chief Executive Officer
Mr. Robert G. Burrows
Vice President of Investor Relations
Ms. Coleen Glessner
Executive Vice President of Global Quality and Ethics & Compliance
Michelle Pepin
Senior VP & Chief Human Resource Officer
Ms. Stephanie Duatschek
Senior VP, Chief Strategy & Transformation Officer
Dr. Kelly Lyn Warfield
Senior VP of Science & Development
Mr. Paul A. Williams
Senior Vice President of Products Business
William Hartzel
Senior Vice President of Manufacturing & Bioservices

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EBS Stock Analysis - Frequently Asked Questions

Should I buy or sell Emergent BioSolutions stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" EBS shares.
View EBS analyst ratings or view top-rated stocks.
What is Emergent BioSolutions' stock price target for 2024?: 2 equities research analysts have issued 12-month price targets for Emergent BioSolutions' stock. Their EBS share price targets range from $9.00 to $22.00. On average, they predict the company's stock price to reach $15.50 in the next year. This suggests a possible upside of 595.1% from the stock's current price.
View analysts price targets for EBS or view top-rated stocks among Wall Street analysts.
How have EBS shares performed in 2023?: Emergent BioSolutions' stock was trading at $11.81 at the start of the year. Since then, EBS stock has decreased by 81.1% and is now trading at $2.23.
View the best growth stocks for 2023 here.
Are investors shorting Emergent BioSolutions?: Emergent BioSolutions saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 10,930,000 shares, an increase of 21.9% from the October 15th total of 8,970,000 shares. Based on an average daily volume of 2,330,000 shares, the short-interest ratio is currently 4.7 days. Approximately 22.0% of the company's stock are short sold.
View Emergent BioSolutions' Short Interest.
How were Emergent BioSolutions' earnings last quarter?: Emergent BioSolutions Inc. (NYSE:EBS) posted its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($0.98) by $0.08. The biopharmaceutical company had revenue of $337.90 million for the quarter, compared to analysts' expectations of $216.17 million. Emergent BioSolutions had a negative trailing twelve-month return on equity of 41.78% and a negative net margin of 72.29%. The firm's revenue for the quarter was up 39.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.86) EPS.
What ETF holds Emergent BioSolutions' stock ?: ETFMG Treatments Testing and Advancements ETF holds 14,243 shares of EBS stock, representing 0.70% of its portfolio.

What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?: 38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees.
What other stocks do shareholders of Emergent BioSolutions own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).
Who are Emergent BioSolutions' major shareholders?: Emergent BioSolutions' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Charles Schwab Investment Management Inc. (3.01%), Jacobs Levy Equity Management Inc. (2.41%), Northern Trust Corp (0.94%), Allspring Global Investments Holdings LLC (0.88%), Invesco Ltd. (0.58%) and American Century Companies Inc. (0.58%). Insiders that own company stock include Kathryn C Zoon, Richard S Lindahl, Robert Kramer, Ronald Richard and Sue Bailey.
View institutional ownership trends.
How do I buy shares of Emergent BioSolutions?: Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:EBS) was last updated on 12/11/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Emergent BioSolutions (EBS) Stock Price, News & Analysis

Emergent BioSolutions MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Emergent BioSolutions Stock (NYSE:EBS)

EBS Stock Price History

EBS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

EBS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™